Related Experiment Videos
Lithium stimulates gene expression through the AP-1 transcription factor pathway
1Molecular Pathophysiology Program, Department of Psychiatry and Behavioral Neurosciences, and Pharmacology, WSU School of Medicine, 5V, DRH, 4201 St. Antoine Blvd., Detroit, MI 48201, USA.
Brain Research. Molecular Brain Research
|August 1, 1998
Summary
Lithium treatment increases the activity of the AP-1 transcription factor, a key pathway for gene expression. This finding may explain lithium
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Lithium is a primary treatment for manic-depressive illness (MDI).
- Its precise mechanism of action, particularly long-term effects, is not fully understood.
- Lithium's therapeutic efficacy and sustained benefits suggest genomic-level actions.
Purpose of the Study:
- To investigate the effect of lithium on gene expression.
- To determine if lithium influences the AP-1 transcription factor pathway.
- To explore the potential role of genomic effects in lithium's mood-stabilizing properties.
Main Methods:
- Utilized human SH-SY5Y and rat C6 glioma cells.
- Assessed AP-1 DNA binding activity following lithium treatment.
- Employed reporter gene assays with SV40 promoter constructs.
- Introduced mutations in AP-1 binding sites to assess their impact.
Main Results:
- Therapeutically relevant lithium concentrations increased AP-1 DNA binding activity in both cell types.
- Lithium enhanced reporter gene activity in a time- and concentration-dependent manner.
- Mutations in AP-1 sites significantly reduced lithium's effect on gene expression.
Conclusions:
- Lithium stimulates gene expression via the AP-1 transcription factor pathway.
- This AP-1 pathway activation may contribute to lithium's long-term mood-stabilizing effects in MDI.
- The findings provide insight into the molecular mechanisms underlying lithium therapy.